Keymed Biosciences Inc. (HKG:2162)
Hong Kong
· Delayed Price · Currency is HKD 53.15
+2.05 (4.01%)
Mar 10, 2026, 10:05 AM HKT
Keymed Biosciences Revenue
Keymed Biosciences had revenue of 498.75M CNY in the half year ending June 30, 2025, with 52.47% growth. This brings the company's revenue in the last twelve months to 872.19M, up 968.17% year-over-year. In the year 2024, Keymed Biosciences had annual revenue of 428.12M with 20.91% growth.
Revenue (ttm)
872.19M CNY
Revenue Growth
+968.17%
P/S Ratio
15.75
Revenue / Employee
593.73K CNY
Employees
1,469
Market Cap
15.05B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Ascletis Pharma | 2.59M |
| Ascentage Pharma Group International | 428.02M |
| Zai Lab | 3.58B |
| Everest Medicines | 932.82M |
| PegBio | -4.25M |
| HBM Holdings | 908.35M |
| InnoCare Pharma | 1.56B |
| Shanghai Haohai Biological Technology | 2.75B |